A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis

Trial ID or NCT#

NCT05314517

Status

not recruiting iconNOT RECRUITING

Purpose

This is a randomized, double-blind, placebo-controlled study with an open-label extension (OLE).

Official Title

A Randomized, Double-blind, Placebo-Controlled Phase 2 Study With Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects With Chronic Pulmonary Sarcoidosis

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Matthew C. Baker, MD MS
Matthew C. Baker, MD MS
Immunologist, Rheumatologist
Assistant Professor of Medicine (Immunology and Rheumatology)

Contact us to find out if this trial is right for you.

Contact

Angie Aberia
650-723-9656

View on ClinicalTrials.gov